Ebola Zaire Protein
Description
Product Specs
Ebolavirus (EVD) is a member of the Filoviridae family, characterized by a single-stranded RNA genome that is non-infectious. The EVD genome, approximately 19,000 base pairs in length, encodes seven genes in the following order: 3'-UTR-NP-VP35-VP40-GP-VP30-VP24-L-5'-UTR. Four distinct ebolaviruses have been identified: Zaire (EBO-Z), Sudan (EBO-S), Cote d'Ivoire (EBO-CI), and Reston (EBO-R), each exhibiting variations in amino acid sequence and gene overlap regions. Ebolaviruses, including EVD, share structural similarities with filoviruses and appear as filamentous particles. These filaments can adopt three primary shapes: shepherd's crook, U-shape, or 6-shape. Additionally, Ebolaviruses may exhibit coiled, toroid, or branched morphologies. Typically, ebolavirions measure around 80nm in width and 14,000nm in length.
The Ebola virus Nucleoprotein (NP) plays a crucial role in immune responses due to its strong antigenicity. This product features the C-terminal fragment of the EBO-Z nucleoprotein, expressed in E. coli and subsequently purified. It exhibits a molecular weight of 15kDa on SDS-PAGE and has an isoelectric point (pI) of 4.87. This Ebola Zaire protein is engineered with a C-terminal histidine tag to facilitate purification, which is achieved using a proprietary chromatographic method.
The Ebola Zaire protein solution is provided in a buffer consisting of Phosphate and 0.02% sodium azide.
The purity of this protein is greater than 95% as determined by SDS-PAGE (12%) using Coomassie blue staining.
To ensure product stability, it is recommended to store the protein at 4°C if the entire vial will be used within 2-4 weeks. For extended storage, freezing at -20°C is advised. Consider adding a carrier protein (0.1% HSA or BSA) for long-term storage to further enhance stability. Avoid subjecting the protein to multiple freeze-thaw cycles to prevent degradation.
This protein is suitable for use in immunoassays.
Product Science Overview
Ebola Zaire Recombinant Protein is a crucial component in the development of vaccines and therapeutic interventions against the Ebola virus, particularly the Zaire strain. This protein is engineered using recombinant DNA technology to express specific antigens that elicit an immune response, providing protection against the virus.
The Ebola virus is a member of the Filoviridae family and is known for causing severe hemorrhagic fever in humans and non-human primates. The Zaire strain, one of the most virulent, has been responsible for several deadly outbreaks. The virus is transmitted through direct contact with bodily fluids of infected individuals or contaminated surfaces.
Recombinant protein technology involves inserting the gene encoding the desired protein into a host cell, such as bacteria, yeast, or mammalian cells. These host cells then produce the protein, which can be harvested and purified for use in vaccines or other therapeutic applications.
The development of the Ebola Zaire Recombinant Protein involves several steps:
- Gene Identification and Cloning: The gene encoding the glycoprotein (GP) of the Zaire Ebola virus is identified and cloned into an expression vector.
- Expression in Host Cells: The vector is introduced into host cells, which are cultured under conditions that promote the expression of the glycoprotein.
- Purification: The expressed glycoprotein is purified from the host cells using various biochemical techniques.
- Characterization: The purified protein is characterized to ensure it retains its antigenic properties and can elicit an immune response.
One of the most notable applications of the Ebola Zaire Recombinant Protein is in the development of the rVSV-ZEBOV vaccine, also known as Ervebo . This vaccine uses a recombinant vesicular stomatitis virus (VSV) vector that expresses the Ebola Zaire glycoprotein. The vaccine has shown high efficacy in preventing Ebola virus disease and has been used in outbreak response efforts .
